Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 January 2025 | Story Charlene Stanley | Photo Supplied
University of the Free State - Main Gate
The THE rankings are known to guide potential students to identify the best institutions for their chosen field of study, allowing them to compare different universities based on the strength of their academic offerings in specific study fields.

The recently published Times Higher Education (THE) World University Rankings by Subject 2025 shows that the University of the Free State (UFS) is ranked among the top 1 000 global higher learning institutions in its nine evaluated subjects, with most subject areas showing improved results from those recorded in 2024. 

The annually published THE World University Rankings by Subject is a highly regarded, trusted global benchmark for academic excellence in specific disciplines. Its methodology is designed to evaluate universities by employing a range of performance indicators categorised under five core pillars, namely Teaching, Research Environment, Research Quality, Industry, and International Outlook. 

Under Teaching, factors such as reputation, student-to-staff ratio, doctorate-to-bachelor ratio, and institutional income are considered. The Research pillar focuses on aspects such as productivity, citation impact, and influence. Among the other considerations are the income generated from industry partnerships and patents, as well as the number of international students, staff, and co-authored publications.

The methodology is carefully adjusted for each subject, ensuring fairness and accuracy by considering field-specific research cultures and publication practices.

The complete list of UFS subject rankings is as follows:

Law: 301+  *
Arts and Humanities: 501-600 # 
Education Studies: 501-600  #
Psychology: 501-600  #
Life Sciences: 601-800  #
Social Sciences: 601-800 #
Medical and Health: 801-1 000  #

Physical Sciences: 801-1 000 #

*The “+” label indicates that there is no upper limit and is used in instances where the THE does not provide exact ranks for universities beyond this position, therefore grouping institutions together to avoid overly fine distinctions at lower ranking tiers. (Eg. 801+ indicates 801st or lower.)

# The range label (eg. 801-1000), indicates that a university is ranked somewhere within this narrower range, (eg. between 801st  and 1000th. )

For more detail, visit: www.timeshighereducation.com

The THE rankings are known to guide potential students to identify the best institutions for their chosen field of study, allowing them to compare different universities based on the strength of their academic offerings in specific study fields. It also often paves the way for research collaboration, as companies are more likely to partner with highly ranked institutions in a specific sector for research and development projects. Furthermore, strong subject rankings enhance the international reputation of universities and enable comprehensive comparison in particular disciplines.

“This type of global benchmarking is extremely valuable in enhancing the international reputation of the UFS, enabling us to ultimately recruit and attract the most talented students and staff from our region and from across the globe. This aligns with our institutional strategy contained in Vision 130, whereby we aim to grow and extend our impact and influence locally, regionally, and globally,” says Prof Anthea Rhoda, acting UFS Vice-Chancellor and Principal. “Valuable knowledge and insights are also garnered during each evaluation process, allowing us to remain a globally competitive force in higher education, and to take the UFS to even greater heights in the years to come.”

Click to view document Click to view UFS Times Higher Subject Scores

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept